Silvant Capital Management’s Cardlytics CDLX Stock Holding History

Silvant Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-377	Closed	-$316K	–	335
2021 Q3	$316K	Sell	377 -243	-39%	-$247K	0.06%	150
2021 Q2	$786K	Hold	620	–	–	0.12%	106
2021 Q1	$680K	Hold	620	–	–	0.12%	110
2020 Q4	$885K	Hold	620	–	–	0.15%	100
2020 Q3	$437K	Hold	620	–	–	0.08%	122
2020 Q2	$434K	Hold	620	–	–	0.08%	118
2020 Q1	$217K	Buy	620 +93	+18%	+$65.9K	0.05%	148
2019 Q4	$331K	Buy	+527	New	+$258K	0.06%	140

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Silvant Capital Management's CDLX Position: Q4 2021 in Review

Silvant Capital Management sold out of Cardlytics (CDLX) in Q4 2021, closing a stake of 377 shares — an estimated $316K sold.

Silvant Capital Management first reported a position in CDLX in Q4 2019 and held it in 8 quarters. The position peaked at $885K in Q4 2020. 163 funds tracked by Wall St. Rank hold CDLX as of Q4 2021.

Silvant Capital Management reported no remaining Cardlytics position as of Q4 2021 after selling out during the quarter.
Silvant Capital Management sold 377 Cardlytics shares in Q4 2021, an estimated $316K.
Silvant Capital Management first reported a position in Cardlytics in Q4 2019 and held it in 8 quarters.
Silvant Capital Management's Cardlytics position peaked at $885K in Q4 2020.
163 funds tracked by Wall St. Rank held Cardlytics as of Q4 2021.

Based on Silvant Capital Management's 13F filing for Q4 2021, filed 7 Feb 2022.